GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » ROC (Joel Greenblatt) %

Summit Therapeutics (Summit Therapeutics) ROC (Joel Greenblatt) % : -2,067.08% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Summit Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2,067.08%.

The historical rank and industry rank for Summit Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

SMMT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -28832.84   Med: -3451.23   Max: 392.28
Current: -1549.39

During the past 13 years, Summit Therapeutics's highest ROC (Joel Greenblatt) % was 392.28%. The lowest was -28832.84%. And the median was -3451.23%.

SMMT's ROC (Joel Greenblatt) % is ranked worse than
73.37% of 1468 companies
in the Biotechnology industry
Industry Median: -334.375 vs SMMT: -1549.39

Summit Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Summit Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Summit Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics ROC (Joel Greenblatt) % Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 392.28 -3,192.18 -3,710.27 -50.67 -404.15

Summit Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,451.03 -844.36 -1,071.02 -2,121.78 -2,067.08

Competitive Comparison of Summit Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Summit Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's ROC (Joel Greenblatt) % falls into.



Summit Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.622) - (11.45 + 0 + 6.146)
=-14.974

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.64) - (12.918 + 0 + 6.821)
=-14.099

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Summit Therapeutics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-161.408/( ( (6.063 + max(-14.974, 0)) + (9.554 + max(-14.099, 0)) )/ 2 )
=-161.408/( ( 6.063 + 9.554 )/ 2 )
=-161.408/7.8085
=-2,067.08 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Summit Therapeutics  (NAS:SMMT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Summit Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (Summit Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Summit Therapeutics (Summit Therapeutics) Headlines